Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M54.7Revenue (TTM) $M--Net Margin (%)--Altman Z-Score6.0
Enterprise Value $M50.7EPS (TTM) $-0.3Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yY
Price/Book1.210-y EBITDA Growth Rate %--Quick Ratio17.9Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio17.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-24.8Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-27.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M56.4ROIC % (ttm)-44.3Gross Margin Increase y-yN

Gurus Latest Trades with BLRX

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

BLRX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


BLRX: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about BLRX:

    News about BLRX:

    Articles On GuruFocus.com
    Analysts Positive on BioLineRx Ltd. Following Ph2 Testing Expansion for AML May 05 2015 
    Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 

    More From Other Websites
    BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences May 19 2016
    BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences May 19 2016
    BioLineRx Reports First Quarter 2016 Financial Results May 17 2016
    BioLineRx Reports First Quarter 2016 Financial Results May 17 2016
    BioLineRx and MaRS Innovation Sign Framework Collaboration Agreement May 16 2016
    BioLineRx and MaRS Innovation Sign Framework Collaboration Agreement May 16 2016
    BioLineRx to Report First Quarter 2016 Results on May 17, 2016 May 10 2016
    BioLineRx to Report First Quarter 2016 Results on May 17, 2016 May 10 2016
    7 Stocks Under $10 to Trade for Big Profits May 06 2016
    BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at... Apr 19 2016
    BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at... Apr 19 2016
    BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval Apr 04 2016
    BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval Apr 04 2016
    BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML Mar 29 2016
    BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML Mar 29 2016
    Best Stocks to Buy Today Wednesday March 23, 2016 Mar 23 2016
    BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization... Mar 23 2016
    BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization... Mar 23 2016
    Biotechs in the News Mar 21 2016
    BIOLINERX LTD. Financials Mar 16 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)